Onco-Innovations Achieves Key Manufacturing Milestone and Appoints New CFO

Onco-Innovations Limited has announced the successful completion of a 300-gram scale-up batch of its A83B4C63 active pharmaceutical ingredient. This milestone supports the development of their drug candidate, ONC010. The process, part of Dalton Pharma Services' program, aimed to establish scalability and reproducibility in manufacturing. Analytical testing confirmed an impressive 99.3% purity, with no detectable residual solvents, marking a significant quality achievement for the ONC010 program.

Additionally, Mr. Dave Antony has been appointed as the new Chief Financial Officer, replacing Mr. Nico Mah. This change is effective immediately. The completion of this batch will aid in future manufacturing processes for clinical studies. Onco-Innovations remains focused on advancing the ONC010 program towards clinical development.